Table 1.

Study population. Demographic, clinical and laboratory data of patients are divided into four groups: CoV2⁺-infected children with persistent symptoms (Long CoV2⁺), at onset (CoV2⁺ onset), after recovery of the symptoms (CoV2⁺ recovered) and CoV2⁻ children. Infected children are subdivided into asymptomatic, with mild and with moderate/severe disease. Patients with severe disease are treated, according to our local protocols, with iv steroids and oxygen support. Patients with mild/moderate disease receive only supportive treatment (iv fluids and antipyretics/pain control).

		Long CoV2+	CoV2+ Onset	CoV2+ Recovered	CoV2− Controls
		n = 51	n = 49	n = 32	n = 9
Age		10.6 ± 4.62	7.1 ± 5.6	7.75 ± 5.5	7.3 ± 5.9
Females		26 (51)	17 (34.7)	20 (62.5)	3 (33.33)
Distance from acute infection (months)		4.2 ± 2.16	0	4.2 ± 2.04	0
Severity of Acute Disease	Asymptomatic	4 (7.8)	6 (12.2%)	4 (12.5)	/
	Mild	42 (82.4)	27 (55.1)	26 (81.25)
	Moderate	5 (9.8)	10 (20.5)	0
	Severe	0	6 (12.2)	2 (6.25)
Persistent symptoms in Long COVID children	Headache	19 (37.2)	/	/	/
	Dyspnea after efforts	15 (29.4)
	Muscle-skeletal pain	12 (23.5)
	Gastrointestinal issues	11 (21.5)
	Fatigue	10 (19.6)
	Chest pain	10 (19.6)
	Tachycardia	6 (11.7)
	Anosmia	5 (9.8)
	Dysgeusia	5 (9.8)
	Skin rashes	5 (9.8)
	Low grade fever	4 (7.8)
	Sleeping problems	4 (7.8)